Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health
January 31, 2022 07:00 ET
|
Madrigal Pharmaceuticals, Inc.
Primary and key secondary endpoints from the double-blind placebo-controlled 969-patient MAESTRO-NAFLD-1 safety study were achieved and demonstrate that resmetirom: Was safe and well-tolerated at 80...
Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st
January 30, 2022 16:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Jan. 30, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases,...
Demand: Global Computer-aided Drug Discovery Market Estimated to Surpass $7,914.2 Million by 2028, and Grow at a CAGR of 15.0% during the Forecast Period [224-Pages] | Divulge By Research Dive
January 25, 2022 09:00 ET
|
Research Dive
New York, USA, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Research Dive states that the global computer-aided drug discovery market is estimated to garner a revenue of $7,914.2 million by 2028, and rise at...
Casana Closes $30 Million Series B Funding to Accelerate Development of Novel Effortless Home Health Monitoring
January 21, 2022 12:15 ET
|
Casana Care, Inc.
ROCHESTER, N.Y., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Casana, a healthcare technology firm that is reinventing in-home health monitoring, announced today that it has raised $30 million in Series B...
Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer
January 10, 2022 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases,...
Opportunities: Computer-aided Drug Discovery Market Expected to Gather a Revenue of $7,914.2 Million by 2028, Growing at a CAGR of 15% from 2021 to 2028 [224-Pages] | Business study by Research Dive
January 04, 2022 09:00 ET
|
Research Dive
New York, USA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Research Dive has added a new report to its offering titled, “Computer-aided Drug Discovery Market by Type (Structure-based Drug Design (SBDD),...
Esperion Appoints Benjamin O. Looker as General Counsel
January 04, 2022 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced the appointment of Benjamin O. Looker as general counsel as of January 1, 2022. Mr. Looker will serve as...
Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom
December 30, 2021 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today provides an update on MAESTRO-NAFLD-1, its 52-week Phase 3 multi-center, double-blind,...
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
November 23, 2021 07:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and...
Positive Resmetirom Data from Completed Open-Label Portion of Phase 3 MAESTRO-NAFLD-1 Clinical Study Presented at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® Digital Experience 2021
November 12, 2021 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
This final read-out of the 52-week open-label resmetirom 100 mg treatment study of 171 patients with presumed non-alcoholic steatohepatitis (NASH) and fibrosis, identified using non-invasive tests,...